
The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …

NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy …

Recent data has shown that England is, on average, slower than Germany, France, Spain and Italy in making orphan medicinal …

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

Rare disease specialist pharma firm Shire, rare disease patient alliance EURORDIS and tech giant Microsoft have announced they have formed …

Shire has revealed that it now plans to move forward by separating its operations into two distinct divisions: rare disease …

Continuing on from this week’s earlier feature on the rare disease situation in the US, Pharmafile moves its attention onto …

With access to rare disease treatments coming under increasing attention, both in the EU and the US, Pharmafile.com took the …

Rare Disease Day falls on the last day of February, meaning every four years it occurs on a leap year, …

NICE has released its decision on the fast-track approval process and other changes that will be brought through at the …

Ionis Pharmaceutial announced that the results of a Phase 3 trial into its treatment for hypertriglyceridemia met its primary endpoint. …

Ireland headquartered Shire (LSE: SHP) on Monday said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation …

Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …

GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …

Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …